Private 1-1 strategy sessions: Discuss hot topics in biotech with our experts

Where AI drives value today

Companies across the biotech value chain recognise the imperative: An actionable Data & AI Strategy is no longer optional. It is one of the most consequential decisions a leadership team will make in the next two years. The question is no longer whether to act, but how to act with focus, intent, and a clear path to measurable impact.

At Deloitte, we partner with organisations to define exactly that: Which capabilities to build, where to place bets, and how to organise to make it real. Critically, this means designing an operating model that embeds reusability at its core, ensuring every investment compounds rather than duplicates, turning strategy into transformation at scale.

Industry experts

• Antonio Russo, European AI Partner
• Laura Stienen, Data & AI Strategy Lead, Senior Manager     
• Vladimir Popov, Strategy & Business Design, Director

The impact of US tariffs on margins and how to mitigate and build a resilient supply chain

What are the latest updates on US tariffs on pharmaceuticals, what are the exemptions and how is the Biotech Industry impacted by it. Also, understand the impact of US trade policies on margins and biotech supply chains and discover practical strategies to minimise cost impact and maintain competitive advantage.

Industry experts

• Hevin Demir, Global Trade and Supply Chain Transparency, Partner
• Dr. Balazs Hargitai, Life Sciences Supply Chain Lead, Director

Launch excellence: Avoid costly mistakes in your product launch

Many biotech companies achieve clinical success but face challenges in translating this into commercial impact. Explore best practices and critical success factors that enable successful product launches and avoid costly mistakes. In a capital-constrained and partnership-driven environment, ensuring alignment with stakeholders and readiness from early market preparation to post-launch execution.  

Industry experts

• Elsa Torchet, Life Sciences Strategy and Business Design, Director
• Peter Baxendell, Strategy, Risk and Transactions, Director

IPO readiness: How ready are you to take your company public?

When and how to access capital markets remain key considerations for Biotech capital strategies. IPO readiness is now considered a permanent operational capability rather than a singular one-time event. In 2026, there have been an increasing number of Biotech companies investing into a foundational level of IPO readiness to ensure they have the agility to take advantage of a clinical data readout or market opening. Understanding your current level of IPO readiness, and the specific areas to implement to be ready, are key to measuring your cost of capital optionality and managing stakeholders’ expectations on timing. Connect with us to explore the typical IPO readiness journey for Biotech.    

Industry experts

• Liam Baynes, Capital Markets Lead, Partner        
• Viktoriya Lombardo, CFO Services, Partner

Enhance your M&A attractiveness: are your operations acquisition ready?

To prepare for a potential future acquisition, you can take proactive steps to strengthen your operational foundation and maximise valuation. Beyond the scientific and clinical merits, potential acquirers will assess the risks of new pipeline assets integration, translating these into value leakage and downside adjustments.

We can discuss how to preserve and enhance perceived value across critical dimensions: data quality, contract transferability, regulatory documentation and integration readiness. By systematically addressing these factors, you can positively influence buyer assessment, command higher valuations, and secure better deal terms.

Industry experts  

• Murielle Launay, Life Science, Partner
• Pierre Farah, Life Sciences M&A and Transformation, Director
• Juliette Odorico, Life Sciences Regulatory Expert, Senior Manager

Compensation for digital opinion leaders and HCPs

Traditional HCP compensation frameworks were built for a world where remuneration was based primarily on time and expertise. Today’s rapidly transforming healthcare landscape compiles organisations to consider influencer metrics, as Digital Opinion Leaders create value throughreach, engagement and peer trust.

Connect with us to explore how to balance scientific expertise, digital reach and regulatory expectations to design a defensible compensation model that enables innovation without increasing compliance risk.

Industry experts

• Kush Varma, US and CH Life Sciences FMV expert, Manager

Navigating the New Era of European Biotech funding and M&A

In a market shaped by late‑stage funding gaps, milestone‑driven collaborations, and rising demand for de‑risked innovation, asset and platform positioning has become critical. At Swiss Biotech Day, we will share practical insights into European funding dynamics and M&A opportunities, tailored for biotech companies seeking growth capital and strategic partnerships.

We will discuss how early, rigorous preparation — combining clear equity storytelling with targeted financial and commercial due diligence — can support value creation and enable more effective engagement with investors, partners, and potential acquirers across Europe.

Industry experts

• Enada Ismailaj, Director, M&A Life Sciences Lead Advisory
• Nicolas Bornitz, Director, M&A Life Sciences Due Diligence & Origination 
  

NIS2 Directive: Cyber risk becomes business risk

How resilient are you towards cyber attacks? The NIS2 Directive (Network and Information Security) shows that the cyber regulatory landscape is evolving and introducing new complexity for organisations. NIS2 raises expectations that organisations take a proactive approach to cyber security introducing new requirements such as management accountability for cyber decisions, comprehensive cyber risk management and a focus on business continuity in the face of a cyber incident. 

As biotech companies scale towards commercialisation, cyber becomes a direct threat to operations, data and reputation, going beyond an IT issue to business risk.  We explore what biotech leaders need to have in place to ensure operational resilience.

Industry experts

• Kishwar Chisty, Life Sciences Risk Advisory, Partner

The future of articulating Health Value

Today, commercial and policy leaders need more than strategy – they need an integrated playbook to address an increasingly complex and challenging landscape. Deloitte's Health Value Creation framework combines Economic Modelling, Market Access, Innovative Financing, and Policy Advisory to help you build defensible, scalable value narratives that unlock sustainable competitive advantage across fragmented markets.

Industry experts

• Andrea Feigl, PhD, Senior Director, Deloitte; CEO and Founder, Health Finance Institute
• Konstantin Ries, Strategy, Risk and Transactions, Senior Manager 

AI governance & AI risk management

AI presents transformative potential and significant business opportunities, fundamentally reshaping how we work, innovate, communicate, and interact socially. While AI offers immense benefits, it also introduces critical risks that require careful governance and management.

Biotech organisations face unique challenges in scaling AI adoption due to these risks. We support them in developing pragmatic and effective AI governance frameworks, incorporating robust risk management practices to mitigate AI-related risks and promote responsible, sustainable AI integration. 
 

Industry experts 

• Kishwar Chisty, Life Sciences Risk Advisory, Partner  
• Elisa Papa, Technology and Transformation, Director